ONKOLOGIE / Onkologie. 2025;19(4):237-242 / www.onkologiecs.cz 242 PŘEHLEDOVÉ ČLÁNKY Stereotaktická radioterapie CyberKnife: účinná a bezpečná modalita v léčbě relabujícího skvamózního karcinomu hlavy a krku LITERATURA 1. Barsouk A, Aluru JS, Rawla P, et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Medical Sciences. 2023;11:42. https://doi.org/10.3390/ medsci11020042. 2. Gillison ML, Chaturvedi AK, Anderson WF, et al. Epidemiology of Human Papillomavirus – Positive Head and Neck Squamous Cell Carcinoma. JCO. 2015;33:3235-3242. https:// doi.org/10.1200/JCO.2015.61.6995. 3. Hobbs CGL, Sterne JAC, Bailey M, et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clinical Otolaryngology. 2006;31:259-266. https:// doi.org/10.1111/j.1749-4486.2006.01246.x. 4. Abrahão R, Perdomo S, Pinto LFR N, et al. Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study. JCO Global Oncology. 2020:486-499. https://doi.org/10.1200/GO.20.00014. 5. Hennessey PT, Westra WH, Califano JA. Human Papillomavirus and Head and Neck Squamous Cell Carcinoma: Recent Evidence and Clinical Implications. J Dent Res. 2009;88:300306. https://doi.org/10.1177/0022034509333371. 6. Franzese C, Louie AV, Kotecha R, et al. Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. Practical Radiation Oncology. 2025;15:e172-188. https://doi.org/10.1016/j. prro.2024.09.011. 7. Gordon K, Smyk D, Gulidov I, et al. An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far? Cancers. 2023;15:4409. https://doi.org/10.3390/cancers15174409. 8. De La Pinta C. SBRT in non-spine bone metastases: a literature review. Med Oncol. 2020;37:119. https://doi.org/10.1007/ s12032-020-01442-1. 9. Cvek J, Kubes J, Skacelikova E, et al. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer: A phase I dose escalation study. Strahlenther Onkol. 2012;188:666-670. https://doi.org/10.1007/s00066-012-0128-x. 10. Heron DE, Rwigema J-CM, Gibson MK, et al. Concurrent Cetuximab With Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: A Single Institution Matched Case-Control Study. American Journal of Clinical Oncology. 2011;34:165-172. https://doi.org/10.1097/ COC.0b013e3181dbb73e. 11. Vargo JA, Moiseenko V, Grimm J, et al. Head and Neck Tumor Control Probability: Radiation Dose–Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group. International Journal of Radiation Oncology Biology Physics. 2021;110:137-146. https://doi.org/10.1016/j.ijrobp.2018.01.044. 12. Rwigema J-CM, Heron DE, Ferris RL, et al. The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy. American Journal of Clinical Oncology. 2011;34:372-379. https://doi.org/10.1097/COC.0b013e3181e84dc0. 13. Cengiz M, Özyiğit G, Yazici G, et al. Salvage Reirradiaton With Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck Tumors. International Journal of Radiation Oncology Biology Physics. 2011;81:104-109. https://doi. org/10.1016/j.ijrobp.2010.04.027. 14. Puthawala A, Nisar Syed AM, Gamie S, et al. Interstitial low- -dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. International Journal of Radiation Oncology Biology Physics. 2001;51:354-362. https://doi.org/10.1016/S0360-3016(01)01637-6. 15. Breen W, Kelly J, Park HS, et al. Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer. Cureus 2018. https://doi.org/10.7759/cureus.2517. 16. Elbers JBW, Al-Mamgani A, Van Den Brekel MWM, et al. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Otolaryngol--Head Neck Surg 2019;160:1023-1033. https://doi. org/10.1177/0194599818818443. 17. Bachar GY, Goh C, Goldstein DP, et al. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol 2010;267:295-301. https://doi.org/10.1007/s00405-009-1070-0. 18. Maruo T, Zenda S, Shinozaki T, M, et al. Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma. Japanese Journal of Clinical Oncology 2020;50:288-295. https://doi.org/10.1093/jjco/hyz176. 19. Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. JCO. 2023;41:790-802. https://doi.org/10.1200/JCO.21.02508. 20. Spaas M, Sundahl N, Kruse V, et al. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9:1205. https://doi. org/10.1001/jamaoncol.2023.2132. HLAVNÍ TÉMA – NOVINKY V LÉČBĚ KARCINOMU PLIC Terapie SLLC Neo/perioperační terapie NSCLC Léčba inoperabilního nemalobuněčného karcinomu plic stadia III Imunoterapie v léčbě metastatického NSCLC Aktuální možnosti cílené léčby nemalobuněčného karcinomu plic v České republice PŘEHLEDOVÉ ČLÁNKY Použití stereotaktické radioterapie v léčbě uveálního melanomu Role T-lymfocytárních subpopulací v patogenezi a léčbě B-nehodgkinských lymfomů Současný stav precizní medicíny v onkologii SDĚLENÍ Z PRAXE Časná diagnostika imunitně podmíněné myozitidy u pacienta léčeného pembrolizumabem Skrytá hrozba: sarkomatoidní transformace germinálního nádoru Pemigatinib v léčbě metastatického intrahepatálního cholangiocelulárního karcinomu s alterací FGFR2 Dezmoplastický melanóm kože vyrastajúci na záhlaví Přinášíme také zajímavá supplementa, novinky z kongresů, a mnoho dalších zajímavostí z oboru … Připravujeme do příští Onkologie 2025 5 ▼ VYCHÁZÍ V PROSINCI
RkJQdWJsaXNoZXIy NDA4Mjc=